Therapie der vulvovaginalen Atrophie

Die vulvovaginale Atrophie ist eine häufige Folge einer abnehmenden Östrogenproduktion, zu der es während der Menopause oder auch durch Tumortherapien kommen kann. Symptome wie vaginale Trockenheit und Schmerzen beim Geschlechtsverkehr sowie ein erhöhtes Risiko für vaginale Milieustörungen, Kolpitiden und Harnwegsinfektionen sind mögliche Folgen. Neben einer hormonellen Therapie existieren wirksame nichthormonelle Behandlungsoptionen.

Kernaussagen

• Der Einfluss einer VVA auf die Lebensqualität ist häufig gravierender als eingeschätzt. Deshalb bedarf es aktiver ärztlicher Information und Beratung zum Thema.

• Eine vaginale Östrogentherapie kann zur Verbesserung von Harninkontinenz und zur Reduktion rezidivierender Harnwegsinfekte bei postmenopausalen Frauen beitragen.

• Auch bei jungen Patientinnen, insbesondere unter adjuvanter Hormontherapie nach Mammakarzinom, ist an eine VVA zu denken.

• Die Datenlage zur CO₂-Lasertherapie bei Patientinnen mit VVA ist eingeschränkt. Ein Vorteil gegenüber anderen gängigen Therapieoptionen hat sich bislang nicht gezeigt.

Schlüsselwörter

vulvovaginale Atrophie - vaginale Östrogentherapie - DHEA - vaginale Lasertherapie - genitourinäres Syndrom der Menopause - Hormontherapie und Krebs

Publication History

Article published online:
31 March 2025

• Literatur

• 1 Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17: 3-9
• 2 Palacios S, Nappi RE, Bruyniks N. et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 2018; 21: 286-291
• 3 Parish SJ, Nappi RE, Krychman ML. et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013; 5: 437-447
• 4 Panay N. Genitourinary syndrome of the menopause--dawn of a new era?. Climacteric 2015; 18 (Suppl. 1) 13-17
• 5 Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric 2014; 17: 557-563
• 6 Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13: 509-522
• 7 Biglia N, Bounous VE, Sgro LG. et al. Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?. Clin Breast Cancer 2015; 15: 413-420
• 8 Mueck AO, Ruan X, Prasauskas V. et al. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric 2018; 21: 140-147
• 9 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. (DGGG). Peri- and Postmenopause – Diagnosis and Interventions. Guideline of the German Society of Gynecology and Obstetrics (S3-Level, AWMF-Registernr. 015–062). 2018 Accessed November 27, 2021 at: https://www.awmf.org/leitlinien/detail/ll/015-062.html
• 10 Mitchell CM, Reed SD, Diem S. et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA Intern Med 2018; 178: 681-690
• 11 Donders G, Neven P, Moegele M. et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014; 145: 371-379
• 12 Labrie F, Archer D, Bouchard C. et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009; 16: 923-931
• 13 Labrie F, Archer DF, Koltun W. et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016; 23: 243-256
• 14 Fedotcheva TA, Uspenskaya ME, Ulchenko DN. et al. Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application. Pharmaceuticals 2024; 17: 1186
• 15 Di Carlo C, Cagnacci A, Murina F. et al. Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women. Expert Opin Pharmacother 2024; 25: 1541-1554
• 16 Støer NC, Vangen S, Singh D. et al. Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. Br J Cancer 2024; 131: 126-137
• 17 Pearson A, Chen J, Dhillon HM. et al. Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review. Breast Cancer Res Treat 2024; 206: 215-226
• 18 Cold S, Cold F, Jensen M-B. et al. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst 2022; 114: 1347-1354
• 19 Agrawal P, Singh SM, Able C. et al. Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer. Obstet Gynecol 2023; 142: 660-668
• 20 McVicker L, Labeit AM, Coupland CAC. et al. Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol 2024; 10: 103-108
• 21 Kovachev SM, Kovachev MS. Genitourinary syndrome, local oestrogen therapy and endometrial pathology: a single-centre, randomised study. J Obstet Gynaecol 2022; 42: 1489-1492
• 22 Leitlinienprogramm Onkologie. S3-Leitlinie „Endometriumkarzinom“. Version 3.0, AWMF-Registernr. 032–034OP. 2024 Accessed November 01, 2024 at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Version_3/LL_Endometriumkarzinom_Langversion_3.0.pdf
• 23 Morris L, Do V, Chard J. et al. Radiation-induced vaginal stenosis: current perspectives. Int J Womens Health 2017; 9: 273-279
• 24 Simon J, Nachtigall L, Ulrich LG. et al. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010; 116: 876-883
• 25 Guidozzi F. Estrogen therapy in gynecological cancer survivors. Climacteric 2013; 16: 611-617
• 26 Shim S-H, Lee SJ, Kim S-N. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 2014; 50: 1628-1637
• 27 Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010; 65: 190-197
• 28 Lester J, Pahouja G, Andersen B. et al. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med 2015; 5: 50-66
• 29 Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev 2018; (05) CD008830
• 30 Wierzbicka A, Mańkowska-Wierzbicka D, Cieślewicz S. et al. Interventions Preventing Vaginitis, Vaginal Atrophy after Brachytherapy or Radiotherapy Due to Malignant Tumors of the Female Reproductive Organs-A Systematic Review. Int J Environ Res Public Health 2021; 18
• 31 Lee Y-K, Chung HH, Kim JW. et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011; 117: 922-927
• 32 Mørch LS, Løkkegaard E, Andreasen AH. et al. Hormone therapy and ovarian cancer. JAMA 2009; 302: 298-305
• 33 Bhupathiraju SN, Grodstein F, Stampfer MJ. et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause 2018; 26: 603-610
• 34 Cody JD, Jacobs ML, Richardson K. et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012; (10) CD001405
• 35 Rahn DD, Carberry C, Sanses TV. et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014; 124: 1147-1156
• 36 Dessole S, Rubattu G, Ambrosini G. et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004; 11: 49-56
• 37 Chen Y-Y, Su T-H, Lau H-H. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J 2021; 32: 17-25
• 38 Anglim B, Phillips C, Shynlova O. et al. The effect of local estrogen therapy on the urinary microbiome composition of postmenopausal women with and without recurrent urinary tract infections. Int Urogynecol J 2022; 33: 2107-2117
• 39 Paraiso MFR, Ferrando CA, Sokol ER. et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause 2020; 27: 50-56
• 40 Dutra PFSP, Heinke T, Pinho SC. et al. Comparison of topical fractional CO2 laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial. Menopause 2021; 28: 756-763
• 41 Salvatore S, Pitsouni E, Grigoriadis T. et al. CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial. Climacteric 2021; 24: 187-193
• 42 Ruanphoo P, Bunyavejchevin S. Treatment for vaginal atrophy using microablative fractional CO2 laser: a randomized double-blinded sham-controlled trial. Menopause 2020; 27: 858-863
• 43 Page A-S, Verbakel JY, Verhaeghe J. et al. Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial. BJOG 2023; 130: 312-319
• 44 Gold D, Nicolay L, Avian A. et al. Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: A randomized controlled trial. Maturitas 2023; 167: 1-7